
First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer
The first patient with small cell lung cancer (SCLC) who has extensive disease has been dosed in a phase 1/2 trial of first-line iadademstat (ORY-1001), a potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibitors, according …